Clinical results of refractive excimer laser ablation of cornea saturated with riboflavin in patients with high myopia

Session Details

Session Title: Photoablation, Cross-Linking and Intracorneal Ring Segment

First Author: M. Mirishova Azerbaijan

Co. Authors :    J. Nazarli   E. Kasimov                 

Abstract Details:


To assess the clinical results of refractive excimer laser ablation of the cornea saturated with riboflavin in patients with high myopia.


National Ophthalmology Center named after acad. Z.Aliyeva, Azerbaijan.


In the clinic transepithelial photorefractive keratectomy (PRK) surgery on saturatied with riboflavin cornea, before its refractive ablation, were performed on 48 eyes (24 patients). In the clinic the operations were performed on the MEL 80 and WaveLight EX 500 excimer lasers. Age of the patients included in the study was from 19 to 42 years. In planning the operation zone of ablation in all patients was 6.5 mm. Residual stromal thikness was an average 320 ± 7.8 microns. Spherical equivalent of refraction in all patients ranged from -6.5 to -9.5 D.


All patients underwent a complete postoperative follow-up at 1, 3, 6 and 12 months. 1 month after the surgery were observed the following results: visual acuity without correction 0.6 ± 0.2; spheroequialent of refraction -0.75 ± 0.25; a cylindrik component 0.75 ± 0.15; the thickness of residual stroma 320 ± 6.4 microns. In none case, there was no evidence of irreversible form of subepithelial fibroplasia. 3 months after the surgery deviation from the estimated refraction not exceeding ± 1.0 D, were noted in 44 of the 48 eyes.


Conducting transepithelial PRK with photoprotection in patients with high myopia accelerates the onset of the complete epithelialization of the cornea, excludes the development of partly reversible and irreversible forms of subepithelial fibroplasia. Technology of photorefractive corneal ablation with photoprotection with riboflavin improves efficiency and expands the arsenal of laser corneal refractive surgery. FINANCIAL INTEREST: NONE